Home > Healthcare > Pharmaceuticals > Vaccines > Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Share

Report ID: GMI5826
Published Date: May 2023
Report Format: PDF

Download Free Sample

Hepatitis B Vaccine Market Share

Major market players operating in the hepatitis B vaccine market include

Merck & Co., Inc
Sanofi S.A.
GlaxoSmithKline plc.
Dynavax Technologies Corporation

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hepatitis B vaccine generated USD 3.3 billion in 2022 and is estimated to grow at 5.1% CAGR and amass USD 5.7 billion by 2032 driven by the high prevalence of chronic infection, liver cirrhosis, and liver cancer.

The combination vaccine segment accounted for over 65% market share in 2022 and is projected to witness robust growth over 2023-2032 owing to their increasing use to provide protection against multiple diseases in a single shot.

The North America hepatitis B vaccine industry held over 40.6% revenue share in 2022 and is set to grow at a considerable rate through 2032 attributed to the high prevalence of hepatitis B infections, coupled with the increasing population at risk, including newborns and healthcare workers.

The top firms operating in the hepatitis B vaccine industry are Merck & Co., Inc, Sanofi S.A., GlaxoSmithKline plc., and Dynavax Technologies Corporation, among others.